SEO URLwww.firestrike.ai/deals/rapt-therapeutics-gsk-acquisition-2026-7
acquisitionAnnounced · Mar 15, 2026biopharmaceuticalSource · SpeculativeArticle · Expectations
GSK acquires RAPT Therapeutics
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$2.2B
Target
RAPT Therapeutics
NASDAQ: RAPT · South San Francisco, California
Acquirer
GSK
Full Acquisition
Status
Pending
GSK agreed to acquire RAPT Therapeutics. Reported deal value: $2.2B. Status: Pending. Sector: biopharmaceutical. Target headquarters context: South San Francisco, California, United States.
This page summarizes publicly available information about the transaction as of 2026-03-15. Figures and status may change as filings and press coverage update.
It Was Just Acquired for $ 58 Per Share Jonathan Ponciano, The Motley Fool Sun, March 15, 2026 at 10:20 PM UTC 0 Key Points OrbiMed Advisors increased its position in RAPT Therapeutics by 5 56 ,273 shares during the fourth quarter
Deal timeline
Announced
Mar 15, 2026 · aol.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biopharmaceutical with a reported deal value of $2.2B. Figures and status may change as sources update.
Sources: aol.com · Primary article · FireStrike proprietary index